Media
Press Releases
September 30, 2025
Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension
September 24, 2025
Lupin Receives Tentative Approval from U.S. FDA for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets
September 3, 2025
Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi’s Long-Acting Injectable Platform
July 24, 2025
Lupin Receives US FDA Approvals for Liraglutide and Glucagon Injectable Products
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product